Start free
Data and Trust

China coverage

How Sleuth covers Chinese programs, and how they show up next to everyone else's.

See China data

Sleuth covers over 22,000 Chinese programs, as of November 2026, from China's own registries, regulators, exchanges, journals, company posts, and broker research.

The Chinese sources

  • Trial registries: ChiCTR, the CDE drug trial registration platform, and ITMCTR.
  • Regulators: NMPA approvals and CDE application, clearance, and priority review lists.
  • Exchanges: HKEXnews, including 18A biotech prospectuses, and CNInfo.
  • Literature: Chinese-language journals, theses, and conference papers.
  • Patents: China National Intellectual Property Administration filings.
  • Company posts: WeChat official accounts of Chinese biotechs and industry media, where pipeline news often appears first.
  • Pricing and statistics: the National Reimbursement Drug List, China CDC, and the National Cancer Center.

How it shows up

Sleuth translates each source and runs it through the same matching and checks as every other source. A Chinese company's program appears in the same table as a US one, under the same drug record, and companies carry both their Chinese and English names. Search in English; you don't need to know the Chinese name.